Roche after H1 sales: Novartis sets the bar

Novartis has been the easier stock to own this month. Roche has been the more interesting company. That split is the whole frame here. Novartis delivered a second-quarter beat on core EPS and the market marked it up, while Roche came in with first-half sales that were softer in reported Swiss franc terms but still solid underneath the currency line. One name is getting rewarded for a cleaner print. The other is asking you to look through translation effects and one product pocket that missed a bit of lift in the U.S.

Roche reported first-half 2026 group sales of CHF 30.36 billion on July 23, down 2% year over year in Swiss franc terms but up 6% at constant exchange rates, and that was in line with analyst expectations around CHF 30.31 billion, according to Reuters. The company also reaffirmed its 2026 outlook for mid-single-digit sales growth and high-single-digit growth in core earnings per share. Shares rose about 5% on the results day to close at CHF 349.50, then traded around CHF 352.10 on July 24, up about 0.7%.

That is the setup. Roche is not asking the market to admire a rescue story. It is asking for patience on a large base, in a sector where constant-currency growth still matters more than the headline translation hit, and where the market has been willing to pay for companies that keep late-stage assets moving while defending guidance. Novartis is the cleaner comp because it has already shown the market a more direct path from earnings to share price. Roche has to earn that same treatment one quarter, one half, one product cycle at a time.

Roche's H1 print against Novartis' cleaner beat

The first thing to separate is reported growth from operational growth. Roche's 2% decline in Swiss franc terms looks weaker than it is because the franc did what the franc does, and the company said constant-currency sales were up 6%. That is not a cosmetic distinction. For a Swiss large cap with global revenue, it is the difference between a headline that looks flat to down and a business that is still expanding at a respectable clip.

Novartis, by contrast, gave the market a cleaner earnings reaction because the quarter landed with less friction. Reuters and market data around the July 21 release showed a beat on core EPS and a share price that moved higher. The market likes a simple story when it can get one. Roche rarely gets one. It has a broader mix, more moving parts, and more exposure to product-specific noise. That makes the comparison useful, because it tells you what the market is paying for right now. It is paying for clarity, not just size.

Roche's own numbers still deserve respect. CHF 30.36 billion in half-year sales is not a company losing its footing. The reaffirmed outlook matters more than the reported decline, because guidance is where management chooses to absorb pain or push it out. Roche chose to keep the full-year frame unchanged, even with a stronger franc and weaker-than-expected U.S. sales of Vabysmo. That is a management decision with some spine in it. It also tells you the company thinks the underlying business can carry the currency drag.

Novartis is the better chart today, but Roche is the larger operating test. If you want a stock that has already been rewarded for execution, Novartis is the cleaner expression. If you want to see whether a global pharma heavyweight can keep its growth story intact while the currency works against it, Roche is the one to watch. The market is not treating those as the same trade.

Vabysmo, the franc, and the part Roche had to absorb

Roche's problem in this release was not a collapse in demand. It was a mix problem. The stronger Swiss franc cut into reported sales, and Vabysmo, the eye drug that investors have been watching closely, came in weaker than expected in the U.S. That combination is enough to make a half-year print look less tidy than the underlying trend would suggest.

This is where Roche differs from Novartis in a way that matters for valuation. Novartis has been able to lean on a more straightforward earnings narrative in recent updates. Roche has to carry a broader set of questions, from diagnostics to oncology to the pace of specific launches. That breadth is an asset when the portfolio is working. It is also a burden when one high-profile product misses the market's hopes. The company can still grow, but the path is less linear.

The market's reaction on July 23 was telling. Roche rose about 5% on the day, which says the bar was not set for perfection. Investors were willing to look through the currency hit because the constant-currency growth was intact and the outlook stayed in place. That is a decent outcome, not a euphoric one. Novartis, with its cleaner beat, got the easier applause. Roche got the more qualified nod.

You can see why the comparison matters. Roche is not trading like a broken story. It is trading like a company that still has to prove that its mix can offset currency and product-specific softness. Novartis has already shown a more direct route to market approval. Roche has to keep doing the heavier work.

No fresh insider prints, which is its own signal

No insider trading activity has been recorded for Roche Holding AG in the last three months, according to Insiderscreener. That is the entire insider record here. No cluster. No lone buy. No opportunistic sale into strength. Just silence.

Silence is not a thesis by itself, and it should not be dressed up as one. But in a name this large, with a half-year update that moved the stock and a peer comparison that is live in the market, the absence of filings matters because it leaves you with only the operating story and the market's reaction to it. There is no fresh boardroom vote of confidence to lean on, and no insider distribution to worry about either. You are left reading Roche the old-fashioned way, through sales, guidance, and how the market prices those against Novartis.

That makes the comparison cleaner, if less dramatic. Novartis has the recent earnings beat and the stronger share response. Roche has the larger half-year sales base, the reaffirmed outlook, and no insider activity to complicate the picture. If there had been a meaningful buy, it would have added a layer of conviction around the H1 message. If there had been a sale, it would have forced a harder question about whether management saw the rally as fully priced. There is neither.

For a reader who wants a filing to do the heavy lifting, this is a disappointment. For a reader who wants the operating update to stand on its own, it is cleaner. Roche's insider record is empty over the last three months, so the stock has to be judged on the same facts the market saw on July 23 and July 24.

The cohort bucket, read beside Roche and Novartis

InsiderTrades data gives the historical T+90 cohort return for this role-and-size bucket, but that is bucket history, not a promise about Roche. The point is to keep the filing read honest. A cohort average can tell you how a similar class of insider event behaved over time. It cannot tell you what Roche will do next, especially when there is no fresh filing to anchor the comparison in the first place.

That caveat matters more here than usual because the story is already being pulled by the operating update and the peer contrast. Novartis has the cleaner near-term tape. Roche has the larger base and the more complicated mix. If you were hoping the insider record would settle the debate, it does not. The bucket data is only a side note, and a cautious one at that.

The better use of the cohort lens is to keep your expectations modest. Roche's current story is not about a dramatic insider cluster or a sudden change in ownership behavior. It is about a company that kept guidance steady after a half-year print that was good enough in constant currency and acceptable to the market in reported terms. The absence of insider activity means the market is not getting a second, private confirmation from management. That leaves the stock to trade on fundamentals and relative positioning against Novartis.

And relative positioning is where the comparison gets sharp. Novartis has already shown that a beat can translate into a cleaner rerating. Roche has shown that a currency hit does not have to break the stock if the underlying business is still growing and guidance stays intact. Those are different messages. The market is paying attention to both.

Valuation is where the comparison gets less polite

Roche and Novartis sit in the same broad Swiss pharma lane, but the market does not price them as interchangeable. Novartis has been rewarded for a more direct earnings path and a stronger recent share reaction. Roche, with its larger sales base and more mixed operating profile, has to justify its multiple through consistency. That is a harder job when the franc is strong and one important U.S. product is softer than expected.

The July 23 move in Roche shares suggests the market was willing to give management the benefit of the doubt. A 5% rise on the day is not trivial. It says the H1 print did enough to reassure holders that the underlying business is still moving. But the follow-through was modest, with the stock around CHF 352.10 on July 24, up about 0.7%. That is what a qualified approval looks like. The market liked the guidance hold. It did not re-rate the name as if the problem were solved.

Novartis, by contrast, has the cleaner valuation argument because the market has a fresher reason to pay up. A beat on core EPS and a stronger share response make the case easier. Roche has to lean on breadth, pipeline, and the resilience of its constant-currency growth. That can work. It just takes more patience, and the market is not famous for handing that out freely.

If you want the blunt version, Roche is the more complete business and Novartis is the more straightforward trade. The market usually prefers straightforward until it does not. Right now, it still does.

What to watch while Roche and Novartis keep diverging

The next checkpoint for Roche is not a dramatic insider event. There is none on the board. It is the next operating update, and whether the company can keep constant-currency growth moving while the franc remains a headwind. Vabysmo will stay on the watch list because the U.S. softness in the half-year print is the kind of detail that can keep a stock from fully participating in a sector rerating.

Novartis remains the cleaner comparator because it has already shown the market a more favorable reaction path. If Roche can keep delivering the kind of constant-currency growth it posted in H1 and avoid another product-specific disappointment, the gap can narrow. If not, the market will keep preferring the stock that gives it less to explain away.

For now, Roche has done enough to avoid a negative read. It has not done enough to overtake Novartis in the market's favor. The company posted CHF 30.36 billion in first-half sales, held guidance, and saw the shares bounce. That is a decent half, not a decisive one. The insider record adds nothing fresh, which is itself a useful fact. The next move will come from the business, not from the filing cabinet.

This is not investment advice.